Semaglutide Reduced Inflammatory Biomarkers in HIV Patients With Lipohypertrophy
DENVER — People with HIV who received semaglutide (Ozempic, Wegovy) had reduced levels of several inflammatory biomarkers associated with cardiovascular disease, a randomized controlled trial showed. After 32 weeks, interleukin (IL)-6 levels decreased by 18.8%, high-sensitivity C-reactive protein (hsCRP) levels decreased by 39.9%, and soluble CD163 levels decreased by 12.3% with the GLP-1 receptor agonist, […]
No Increased Risk of Suicidal Ideation With GLP-1 Drugs
Despite recent concerns to the contrary, semaglutide (Wegovy, Ozempic) carried a lower risk of suicidal ideation in patients with obesity or type 2 diabetes, according to retrospective analyses of the two patient populations. An analysis of 240,618 patients who were overweight or obese showed that those taking semaglutide — a glucagon-like peptide 1 (GLP-1) receptor […]
Semaglutide’s Weight-Loss Benefit Also Seen in Patients on Antidepressants
DALLAS — People taking antidepressants lost a similar amount of weight on semaglutide 2.4 mg (Wegovy) compared with those not taking antidepressants, according to a post-hoc analysis of four STEP trials. Participants on antidepressants taking the GLP-1 receptor agonist lost an average 10.7% to 19% of their baseline body weight compared to a 9.5% to […]
Weight-Loss Drug Benefit Spans HFpEF, HFmrEF
CLEVELAND — Semaglutide 2.4 mg (Wegovy) improved outcomes across the range of moderately reduced and preserved ejection fraction in heart failure (HFmrEF, HFpEF) related to obesity, a prespecified secondary analysis of the STEP-HFpEF trial showed. The benefits were consistent across subgroups, reported Javed Butler, MD, MPH, MBA, of the Baylor Scott and White Research Institute […]
Could Semaglutide Help Curb Addictive Behaviors?
Semaglutide (Ozempic, Wegovy) and other drugs in its class are widely known for their role in managing type 2 diabetes and suppressing appetite. They may also prove helpful one day in curbing certain addictive behaviors like alcohol use and smoking. Preclinical research has shown promising results, and endocrinologists and patients have described, anecdotally, reduced cravings […]
Quarter of Wegovy-Treated Teens With Obesity Return to Normal Weight
Far more teens with obesity treated with 2.4 mg semaglutide (Wegovy) returned to normal weight or dropped below the obesity threshold compared with placebo-treated patient, a secondary analysis of the phase IIIa STEP TEENS trial found. During the 68-week trial, 44.9% of teens with obesity returned to either normal weight or went down to the […]
Demand Rising for ‘Bootlegged’ Weight-Loss Drug
Novo Nordisk’s weight management drug semaglutide (Wegovy) has been in prolonged short supply due to “unprecedented demand,” prompting increased — and questionable — interest in compounded formulations of the drug, physicians said. Endocrinologists and obesity medicine specialists have been sounding the alarm about what they say amounts to bootleg semaglutide, concerned about safety and quality […]